NCT07118254招募中2 期
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 3
- 主要终点
- To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatment
研究概览
简要总结
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have the ability to comprehend and provide a signed and dated consent form.
- •Are 18-80 years of age at time of consent;
- •Have been diagnosed with oGVHD for at least 3 months prior to giving informed consent to participate in the trial;
- •Current use of artificial tears for the treatment of oGVHD related dry eye;
- •Have been stably using systemic medications for at least 14 days prior to Visit 1;
- •VAS Eye Dryness (100-point scale) score ≥ 40 mm;
- •Average VAS score for all symptoms of dry eye (dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) ≥ 25 mm, none < 5 mm;
- •Have Oxford corneal fluorescein staining grade of ≥ 2 using the Oxford scale in the worst performing eye
- •Stated willingness to comply with all study procedures, attend all scheduled clinic visits, and continue participation for the duration of the study;
- •Ability to self-administer study medication and willingness to adhere to the medication regimen.
排除标准
- •Are currently or have a history of any ocular or systemic disorder or condition other than dry eye that based on investigator judgment will interfere with the interpretation of the study results. Examples of ocular or systemic disorders or conditions include active ocular infection, conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis, moderate to severe blepharitis, ocular trauma, progressive or degenerative corneal conditions, uveitis, and systemic infection;
- •History of any ocular surgery (including laser or refractive surgical procedures) or therapeutic medical devices in either eye within 30 days before study enrollment. Therapeutic medical devices include trigeminal stimulation, meibomian glad warming (excepting at home masks) or expression, intense pulsed light, low level light therapy, etc. Ocular surgeries include laser or refractive surgical procedures, insertion of punctal or punctal cauterization; Ocular surgery will not be allowed during study participation;
- •Initiation of new therapeutic modalities within 14 days of Visit 1;
- •Have a known hypersensitivity to one of the components of the study or procedural medications;
- •Have participated in another clinical study at the same time as the present study or within 30 days of the Visit 1;
- •Have a history of drug, medication or alcohol abuse or addiction;
- •Are females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) who meet any one of the following conditions:
- •are currently pregnant or,
- •have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
- •intend to become pregnant during the entire course of and 30 days after the study treatment periods, or,
- •are breast-feeding or,
- •not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods;
- •Per the discretion of the investigator or designee, history of a serious physical or mental disorder that prevents the subject from attending study visits, complying with study-related procedures, and/or prevents the subject's ability to make decisions on their own;
- •Any other surgical or medical condition or finding that in the opinion of the investigator would compromise the subject's safety or participation in the study.
研究组 & 干预措施
rhPRG4 450ug/ml
Experimental
rhPRG4 450ug/ml
干预措施: rhPRG4 450ug/ml (Drug)
Vehicle Control
Placebo Comparator
PBS Based Vehicle Control
干预措施: Vehicle Control (Drug)
结局指标
主要结局
To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatment
时间窗: Baseline to day 28
To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatment
To assess the efficacy of rhPRG4 using the total VAS score (sum of dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia, anchors: none & severe) compared to vehicle after 28 days of treatment
时间窗: From baseline to day 28
To assess the efficacy of rhPRG4 using the total VAS score (sum of dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia, anchors: none \& severe) compared to vehicle after 28 days of treatment
次要结局
- To assess the safety of rhPRG4 by observation of the Best Corrected Distance Visual Acuity (BCVA)(From baseline to day 28)
- To assess the efficacy of rhPRG4 using individual VAS scores for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none & severe) compared to vehicle after 28 days of treatment(From baseline to day 28)
- To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle after 28 days of treatment(From baseline to day 28)
- To assess the efficacy of rhPRG4 using the maximum inter-eye tear osmolarity: max(OU) compared to vehicle after 28 days of treatment(From baseline to day 28)
- To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events over the study duration(From baseline to day 28)
- To assess the safety of rhPRG4 by observation of signs evaluated by safety examination (ophthalmic examination plus slit lamp examination (SLE) of meibomian glands, eyelid Erythema, eyelid oedema, lashes, conjunctival erythema, lens, iris, anterior chamb(From baseline to day 28)
- To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)(From baseline to day 28)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
不适用
A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOVEAL AGE-RELATED MACULAR DEGENERATION (AMD)MedDRA version: 6.1Level: PTClassification code 10025409AGE-RELATED MACULAR DEGENERATIONEUCTR2004-001301-10-ITPFIZER135
招募中
2 期
OKG-0301 for the Treatment of Acute Adenoviral ConjunctivitisViral ConjunctivitisAdenoviral ConjunctivitisInfectious ConjunctivitisEye - Diseases / disorders of the eyeInfection - Other infectious diseasesACTRN12619000177156Okogen Pty Ltd219
进行中（未招募）
不适用
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME).Diabetic macular edema (DME)MedDRA version: 17.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2013-003147-27-DEPfizer Inc 235 East 42nd Street, New York, NY 10017 US200
进行中（未招募）
1 期
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME).Diabetic macular edema (DME)MedDRA version: 19.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2013-003147-27-CZPfizer Inc 235 East 42nd Street, New York, NY 10017 US200
进行中（未招募）
不适用
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME).Diabetic macular edema (DME)MedDRA version: 17.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2013-003147-27-PLPfizer Inc 235 East 42nd Street, New York, NY 10017 US200